## Filipa Mascarenhas-Melo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7557323/publications.pdf

Version: 2024-02-01

758635 940134 17 642 12 16 citations g-index h-index papers 17 17 17 1049 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Nanocarrier-based dermopharmaceutical formulations for the topical management of atopic dermatitis. International Journal of Pharmaceutics, 2022, 618, 121656.	2.6	18
2	Nanocarriers for the topical treatment of psoriasis - pathophysiology, conventional treatments, nanotechnology, regulatory and toxicology. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 176, 95-107.	2.0	17
3	Plant-mediated green synthesis of metal-based nanoparticles for dermopharmaceutical and cosmetic applications. International Journal of Pharmaceutics, 2021, 597, 120311.	2.6	104
4	The Relationship between Nutritional Status and Functional Capacity: A Contribution Study in Institutionalised Portuguese Older Adults. International Journal of Environmental Research and Public Health, 2021, 18, 3789.	1.2	8
5	Ethosomes as Nanocarriers for the Development of Skin Delivery Formulations. Pharmaceutical Research, 2021, 38, 947-970.	1.7	74
6	Nanotechnology-based formulations toward the improved topical delivery of anti-acne active ingredients. Expert Opinion on Drug Delivery, 2021, 18, 1435-1454.	2.4	8
7	Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovascular Diabetology, 2013, 12, 61.	2.7	56
8	Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin. Mediators of Inflammation, 2013, 2013, 1-12.	1.4	21
9	Markers of Increased Cardiovascular Risk in Postmenopausal Women: Focus on Oxidized-LDL and HDL Subpopulations. Disease Markers, 2013, 35, 85-96.	0.6	32
10	Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid. Scientific World Journal, The, 2013, 2013, 1-16.	0.8	7
11	New Markers of Early Cardiovascular Risk in Multiple Sclerosis Patients: Oxidized-LDL Correlates with Clinical Staging. Disease Markers, 2013, 34, 341-348.	0.6	56
12	New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging. Disease Markers, 2013, 34, 341-8.	0.6	27
13	Main Determinants of PON1 Activity in Hemodialysis Patients. American Journal of Nephrology, 2012, 36, 317-323.	1.4	16
14	Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. Journal of Pharmacy and Bioallied Sciences, 2011, 3, 350.	0.2	24
15	Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat). Experimental Diabetes Research, 2011, 2011, 1-12.	3.8	128
16	Differential Effects of Acute (Extenuating) and Chronic (Training) Exercise on Inflammation and Oxidative Stress Status in an Animal Model of Type 2 Diabetes Mellitus. Mediators of Inflammation, 2011, 2011, 1-8.	1.4	38
17	Application of nanotechnology in management and treatment of diabetic wounds. Journal of Drug Targeting, 0, , 1-21.	2.1	8